MT3 and hepatocellular carcinoma: Subsequent analyses of HCC-diagnosed cohorts revealed that MT3 can be found to be up-regulated in HCC tissues, and more importantly, its high expression is closely associated with poor therapeutic outcomes of HCC subjects treated with sorafenib.